A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

Suzanne Leijen; Patricia M. M. B. Soetekouw; T. R. Jeffry Evans; Marianne Nicolson; Jan H. M. Schellens; Maria Learoyd; Lynda Grinsted; Victoria Zazulina; Thinn Pwint; Mark Middleton

doi:10.1007/s00280-011-1732-7

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

Suzanne Leijen, Patricia M. M. B. Soetekouw, T. R. Jeffry Evans, Marianne Nicolson, Jan H. M. Schellens, Maria Learoyd, Lynda Grinsted, Victoria Zazulina, Thinn Pwint, Mark Middleton

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1619-1628
Journal	Cancer Chemotherapy and Pharmacology
Volume	68
Issue number	6
DOIs	https://doi.org/10.1007/s00280-011-1732-7
Publication status	Published - Dec 2011

Keywords

MEK 1/2 inhibitor
Selumetinib
Phase I
Food effect

Access to Document

10.1007/s00280-011-1732-7

Cite this

Leijen, S., Soetekouw, P. M. M. B., Evans, T. R. J., Nicolson, M., Schellens, J. H. M., Learoyd, M., Grinsted, L., Zazulina, V., Pwint, T., & Middleton, M. (2011). A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 68(6), 1619-1628. https://doi.org/10.1007/s00280-011-1732-7

Leijen, Suzanne ; Soetekouw, Patricia M. M. B. ; Evans, T. R. Jeffry ; Nicolson, Marianne ; Schellens, Jan H. M. ; Learoyd, Maria ; Grinsted, Lynda ; Zazulina, Victoria ; Pwint, Thinn ; Middleton, Mark. / A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. In: Cancer Chemotherapy and Pharmacology. 2011 ; Vol. 68, No. 6. pp. 1619-1628.

@article{48ab5aeb3f9a4b89bd5ed9f3330dfe0f,

title = "A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors",

keywords = "MEK 1/2 inhibitor, Selumetinib, Phase I, Food effect",

author = "Suzanne Leijen and Soetekouw, {Patricia M. M. B.} and Evans, {T. R. Jeffry} and Marianne Nicolson and Schellens, {Jan H. M.} and Maria Learoyd and Lynda Grinsted and Victoria Zazulina and Thinn Pwint and Mark Middleton",

year = "2011",

month = dec,

doi = "10.1007/s00280-011-1732-7",

language = "English",

volume = "68",

pages = "1619--1628",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "6",

}

Leijen, S, Soetekouw, PMMB, Evans, TRJ, Nicolson, M, Schellens, JHM, Learoyd, M, Grinsted, L, Zazulina, V, Pwint, T & Middleton, M 2011, 'A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors', Cancer Chemotherapy and Pharmacology, vol. 68, no. 6, pp. 1619-1628. https://doi.org/10.1007/s00280-011-1732-7

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. / Leijen, Suzanne; Soetekouw, Patricia M. M. B.; Evans, T. R. Jeffry; Nicolson, Marianne; Schellens, Jan H. M.; Learoyd, Maria; Grinsted, Lynda; Zazulina, Victoria; Pwint, Thinn; Middleton, Mark.

In: Cancer Chemotherapy and Pharmacology, Vol. 68, No. 6, 12.2011, p. 1619-1628.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

AU - Leijen, Suzanne

AU - Soetekouw, Patricia M. M. B.

AU - Evans, T. R. Jeffry

AU - Nicolson, Marianne

AU - Schellens, Jan H. M.

AU - Learoyd, Maria

AU - Grinsted, Lynda

AU - Zazulina, Victoria

AU - Pwint, Thinn

AU - Middleton, Mark

PY - 2011/12

Y1 - 2011/12

KW - MEK 1/2 inhibitor

KW - Selumetinib

KW - Phase I

KW - Food effect

U2 - 10.1007/s00280-011-1732-7

DO - 10.1007/s00280-011-1732-7

M3 - Article

VL - 68

SP - 1619

EP - 1628

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -

Leijen S, Soetekouw PMMB, Evans TRJ, Nicolson M, Schellens JHM, Learoyd M et al. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2011 Dec;68(6):1619-1628. https://doi.org/10.1007/s00280-011-1732-7